ALLERGY THERAPEUTICS PLC

Board/Management Information • Nov 18, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2671X

Allergy Therapeutics PLC

18 November 2014

18 November 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or the 'Company")

Appointment of a Non-Executive Director

Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, is pleased to announce that it has appointed, with immediate effect, Jean-Yves Pavée as a Non-Executive Director; nominated by Abbott (NYSE: ABT).

Jean-Yves Pavée is Senior Vice President, Developed Markets for Abbott's Established Products Division.  He was appointed to his role in July 2013.  Previously, he served as Divisional Vice President, EMEA East, and Division Vice President, Pharmaceuticals, Europe South.  He joined Abbott in 1992.

Peter Jensen Chairman of Allergy Therapeutics commented:

"We are delighted towelcome Jean-Yves to the Board.  He brings extensive industry experience, which will be invaluable toour Company as we continue to execute our global strategy."

Additional information regarding Jean-Yves Pavée:

Full name and age: Jean-Yves Frédéric Georges André Pavée-Callu, aged 51

There are no further disclosures required under Schedule Two paragraph (g) of the AIM rules.

For further information

Allergy Therapeutics	+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
Peel Hunt LLP	+44 (0) 20 7418 8900
James Steel
Clare Terlouw
FTI Consulting	+44 (0) 20 3727 1000
Simon Conway
Victoria Foster Mitchell

Note to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination.  Ithas a growing business achieving revenue in thelast financial yearof £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.  The Company is expanding its infrastructure into theEmerging markets

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAEFXFASLFAF